Abstract

OFATUMUMAB: FOR RELAPSING FORMS OF MULTIPLE SCLEROSIS

Harichandana Punukula*, Puligari Praveen Reddy, Kallem Sharat Venkat Reddy

ABSTRACT

Kesimpta (ofatumumab) is a CD20- directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. MS: MS is an autoimmune disease in which the body’s immune system mistakenly attacks and damages the myelin sheath, the protective protein layer that insulates nerve fibers. The exact mode of action by which Kesimpta alters relapse and remission in MS is still uncertain. Researchers know that the treatment targets B-cells by binding to the CD20 protein found on their surface. They think that this leads to a decrease in the number of these immune cells that attack the myelin sheath. The most common side effects for ofatumumab (Arzerra) include infusion reactions and neutropenia. The most common side effects for ofatumumab (Kesimpta) include upper respiratory tract infection, headache, injection-related reactions, and local injection site reactions.

Keywords: .